Drug Profile


Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; Allogeneic mesenchymal-like adherent stromal cells; PLacental eXpanded cells; PLX-PAD cell therapy

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pluristem Therapeutics
  • Class Ischaemic heart disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia; Thromboangiitis obliterans
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Peripheral arterial disorders
  • Phase II Intermittent claudication; Muscle injury
  • Preclinical Duchenne muscular dystrophy; Graft-versus-host disease
  • No development reported Ischaemic heart disorders; Preeclampsia; Pulmonary arterial hypertension; Tendon injuries

Most Recent Events

  • 06 Nov 2017 Preclinical trials in Graft-versus-host disease in Israel (Parenteral)
  • 06 Nov 2017 Pluristem Therapeutics and Tel Aviv Sourasky Medical Center plan a phase I/II trial for Graft-versus-host-disease in Israel
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension in Australia (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top